JP2023113636A5 - - Google Patents

Info

Publication number
JP2023113636A5
JP2023113636A5 JP2023077286A JP2023077286A JP2023113636A5 JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5 JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5
Authority
JP
Japan
Prior art keywords
antibody polypeptide
polypeptide
single variable
variable domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023077286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023113636A (ja
Filing date
Publication date
Priority claimed from JP2019564951A external-priority patent/JP2020521458A/ja
Application filed filed Critical
Publication of JP2023113636A publication Critical patent/JP2023113636A/ja
Publication of JP2023113636A5 publication Critical patent/JP2023113636A5/ja
Pending legal-status Critical Current

Links

JP2023077286A 2017-05-25 2023-05-09 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 Pending JP2023113636A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762511245P 2017-05-25 2017-05-25
US62/511,245 2017-05-25
JP2019564951A JP2020521458A (ja) 2017-05-25 2018-05-24 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物
PCT/US2018/034330 WO2018217988A1 (en) 2017-05-25 2018-05-24 MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019564951A Division JP2020521458A (ja) 2017-05-25 2018-05-24 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物

Publications (2)

Publication Number Publication Date
JP2023113636A JP2023113636A (ja) 2023-08-16
JP2023113636A5 true JP2023113636A5 (cg-RX-API-DMAC10.html) 2025-11-28

Family

ID=62599725

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564951A Pending JP2020521458A (ja) 2017-05-25 2018-05-24 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物
JP2023077286A Pending JP2023113636A (ja) 2017-05-25 2023-05-09 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019564951A Pending JP2020521458A (ja) 2017-05-25 2018-05-24 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物

Country Status (6)

Country Link
US (2) US20200148779A1 (cg-RX-API-DMAC10.html)
EP (1) EP3630832A1 (cg-RX-API-DMAC10.html)
JP (2) JP2020521458A (cg-RX-API-DMAC10.html)
KR (2) KR102847736B1 (cg-RX-API-DMAC10.html)
CN (1) CN110637035A (cg-RX-API-DMAC10.html)
WO (1) WO2018217988A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7762645B2 (ja) * 2019-08-22 2025-10-30 シダラ セラピューティクス インコーポレーテッド バリアントfcドメイン及びその使用
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230140384A1 (en) * 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度
CN115867580A (zh) 2020-05-18 2023-03-28 百时美施贵宝公司 具有改进的药代动力学特性的抗体变体
CN112552389B (zh) * 2020-08-07 2023-06-06 中爱瑞祥(杭州)生物科技有限公司 一种活性肽融合蛋白及其制备方法
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US9051373B2 (en) * 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
NO2699601T3 (cg-RX-API-DMAC10.html) 2011-04-21 2018-06-16
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
PE20181367A1 (es) * 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Similar Documents

Publication Publication Date Title
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
US10442857B2 (en) Anti-IL-17 antibodies
ES2569217T3 (es) Agente para tratar enfermedades
JP2020184996A5 (cg-RX-API-DMAC10.html)
US7179465B2 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon
JP2022507741A5 (cg-RX-API-DMAC10.html)
JP2020521458A5 (cg-RX-API-DMAC10.html)
JP2020193210A5 (cg-RX-API-DMAC10.html)
KR101256400B1 (ko) 항체
JP2023120208A5 (cg-RX-API-DMAC10.html)
JP2014530611A5 (cg-RX-API-DMAC10.html)
RU2008152443A (ru) Антитела высокой аффинности к il-6-рецептору человека
JP2017099391A5 (cg-RX-API-DMAC10.html)
JP2020532285A5 (cg-RX-API-DMAC10.html)
JP7680078B2 (ja) 抗ヒトインターフェロンα受容体1モノクローナル抗体及びその使用
JP2010500005A5 (cg-RX-API-DMAC10.html)
KR20140108520A (ko) CD1d에 대한 항체
CN112105373A (zh) 治疗b型肝炎病毒感染的方法
TW202320782A (zh) 癌症治療組合
JP2025530888A5 (cg-RX-API-DMAC10.html)
WO2023185957A1 (zh) 抗体、融合蛋白及其用途
AU2017313632B2 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
JP2017536821A5 (cg-RX-API-DMAC10.html)
EP4028056A1 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
AU7782894A (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon